Retatrutide Explained: What an Obesity Medicine Doctor Wants You to Know

How Retatrutide Compares to Semaglutide and Tirzepatide

To understand why Retatrutide is generating so much buzz, it helps to see how it fits alongside the two GLP-1 medications already approved by the FDA.

“That third pathway, glucagon, is really what makes Retatrutide so interesting,” says Dr. Chaudhary.

Why the Glucagon Pathway Has Researchers Excited

Glucagon behaves differently from GLP-1 and GIP. Early research suggests it may increase energy expenditure and push the liver to burn stored fat, particularly relevant for liver fat metabolism, rather than simply reducing appetite.

“There is early evidence from the studies that it may increase how many calories the body burns at rest, independent of how much you’re eating,” Dr. Chaudhary notes. “Researchers think that Retatrutide might do more than simply make people eat less.”

She’s careful, though, to separate what is proven from what is still theoretical.

“This is where the internet gets ahead of the science,” she cautions. “We have a good biological reason to believe that the glucagon component of Retatrutide can increase energy expenditure, but we don’t know yet how much of the weight loss is coming from increased energy expenditure versus reduced food intake and other metabolic effects of the medication.”

What Does the Research Actually Show?

According to Dr. Chaudhary, the early data is striking, but it needs context.

“At the highest dose studied in the phase 2 trials, the average weight loss was around 24% at 48 weeks,” she says. “Those are pretty impressive numbers, but I always like to put the numbers into context first. Phase 2 trials are relatively small compared with the large phase 3 trials, which are used to establish safety and efficacy before a medication is approved by the FDA. Phase 3 data can look very different from phase 2 data.”

Manufacturer Eli Lilly has since moved Retatrutide into a Phase 3 trial program, and industry outlet BioPharma Dive reports the company is preparing to file for FDA approval based on the new results. You can review the official trial listing on ClinicalTrials.gov and Eli Lilly’s own patient-facing overview of the medication using the link below.

Is Retatrutide FDA-Approved?

No. As of now, Retatrutide is still investigational and has not been approved by the FDA. It is only available through clinical trials, and it is not legal or safe to purchase from online sellers claiming to offer it.

“If the phase 3 studies continue to show positive results and the FDA approves Retatrutide, it eventually could become a very important option for treating patients with obesity,” Dr. Chaudhary says. “Until that happens, it is still not an FDA-approved treatment.”

Why You Shouldn’t Try to Buy Retatrutide Right Now

This is the part Dr. Chaudhary wants patients to hear most. Because Retatrutide isn’t FDA-approved, anything sold online under that name is not a regulated pharmaceutical product. There is no way to verify its purity, dosing accuracy, or manufacturing quality, and no physician oversight to catch complications early.

“If you’re interested in Retatrutide, my advice is: don’t buy it from a random website,” she says. “Don’t assume something labeled Retatrutide is actually pharmaceutical-grade Retatrutide. Talk to your obesity physician about what is actually available and what is actually appropriate for you right now, and keep watching the research. I think Retatrutide is one of the most interesting developments I’ve seen in obesity medicine in quite some time.”

We share her excitement about where this research is headed. But excitement is exactly why caution matters here: the more promising a medication looks, the more important it is to wait for the safeguards that come with FDA approval and a legitimate prescription.

You Don’t Have to Wait to Start: FDA-Approved Options Available Today

The good news is that patients don’t need to wait for Retatrutide to begin treatment. Semaglutide and tirzepatide are both FDA-approved and available now, under the supervision of a qualified obesity medicine physician.

“With any medication that produces significant weight loss, whether it’s semaglutide, tirzepatide, or eventually retatrutide, the goal should not simply be to watch the number go down on the scale,” Dr. Chaudhary explains.

More Than a Number on the Scale: A Whole-Patient Approach

Dr. Chaudhary is quick to point out that no GLP-1 medication, current or future, works in isolation.

“When people lose weight, they can lose both fat and lean body mass, including muscle. That’s why I don’t believe obesity treatment should ever be just about giving someone an injection and sending them on their way,” she says. “We want to think about the whole patient: nutrition, adequate protein intake, resistance training, and behavioral support, and, when appropriate, monitoring body composition so we can identify excessive muscle loss and adjust the treatment plan accordingly.”

At Nova Physician Wellness Center, that means a team-based approach that includes obesity medicine physicians, dietitians, nutritionists, and behavioral health support.

“Ultimately, the medication is a tool,” Dr. Chaudhary says. “The goal isn’t just to lose weight. The goal is to improve your health, preserve as much muscle as you can, and build a treatment plan you can actually maintain for the long term.”

Frequently Asked Questions

What Is Retatrutide?

Retatrutide is an investigational injectable medication currently being studied for chronic weight management. It belongs to a class of drugs that mimic gut hormones involved in appetite and blood sugar regulation, the same family that includes semaglutide and tirzepatide, but it is designed to act on three separate hormone pathways instead of just one or two.

“Over the last several years, we have seen these medications evolve by targeting different hormone pathways involved in appetite, metabolism, and blood sugar regulation,” explains Dr. Chaudhary.

About Dr. Seema Chaudhary, MD

Dr. Seema Chaudhary is a board-certified obesity medicine and preventive medicine physician with more than 15 years of clinical experience. She completed her residency at the University of Florida in Gainesville and began her career serving underserved populations at Community Health Center Clearwater before practicing with Kaiser Permanente in Northern Virginia. Today, she directs multiple obesity medicine centers across Maryland and Virginia at Nova Physician Wellness Center, where she and her team manage patients on GLP-1 and other incretin-based treatments every day. She was recognized as one of Arlington Magazine’s Top Doctors for her commitment to patient care and clinical excellence. Read her full bio here.

Sources & Further Reading

• Eli Lilly and Company, “What to Know About Retatrutide”
• BioPharma Dive, “Lilly, with new data, to seek FDA approval of obesity drug retatrutide”
• ClinicalTrials.gov, Study NCT05882045
• Dr. Seema Chaudhary, MD, provider bio, Nova Physician Wellness Center
  

Ready to Talk to an Obesity Medicine Physician?

Whether you’re curious about Retatrutide, exploring FDA-approved options like semaglutide or tirzepatide, or simply want a comprehensive, whole-patient approach to weight management, Dr. Chaudhary and the team at Nova Physician Wellness Center are here to help. Call 703-865-6490 or schedule a consultation online to get started.